Maternal Serum Alpha-Fetoprotein as a Biomarker for Placental Adherence in Low-Lying Placenta: A Prospective Observational Study at a Tertiary Care Centre in Eastern India
International Journal of Current Pharmaceutical Review and Research · 30.07.2026 · 18 (07)
DOI: 10.25258/ijcpr.18.7.12 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.07.2026. Verfasst von Priyanka V V und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Placenta accreta spectrum (PAS) is a potentially life-threatening obstetric condition associated with severe maternal hemorrhage, hysterectomy, intensive care admission, and adverse neonatal outcomes. Early diagnosis remains challenging, particularly in resource-limited settings where advanced imaging modalities are not readily available.
Objectives
To evaluate maternal serum alpha-fetoprotein (MSAFP) as a biomarker for placental adherence in women with low-lying placenta and to assess associated fetomaternal outcomes. Materials and Methods: A prospective observational study was conducted in the Department of Obstetrics and Gynaecology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, over one year. Sixty antenatal women with ultrasonographically documented low-lying placenta or placenta previa in the third trimester were included. Maternal serum AFP levels were measured by ELISA and correlated with intraoperative findings and fetomaternal outcomes.
Results
Among 60 women studied, 8 (13.3%) had PAS. Mean MSAFP levels were significantly higher among PAS cases compared to non-PAS cases (731.92 ± 421.37 ng/mL vs. 155.53 ± 69.73 ng/mL; p250 ng/mL) was observed in 100% of PAS cases compared with only 7.7% of non-PAS cases. Placenta accreta accounted for 62.5% of PAS cases, placenta increta 12.5%, and placenta percreta 25%. All PAS cases underwent cesarean hysterectomy. Maternal morbidity was significantly higher in PAS cases, including ICU admission, bladder injury, and vesicovaginal fistula. One maternal death and one early neonatal death were reported.
Conclusion
MSAFP is a promising, inexpensive, and easily accessible biomarker for the early identification of PAS in women with low-lying placenta. Its incorporation into antenatal risk assessment may facilitate timely referral and improve maternal and neonatal outcomes.
Zitieren
APA
V, P. V., Meena, R., Boipai, P., Mehta, M., DungDung, I. R., & Chaudhary, K. (2026). Maternal Serum Alpha-Fetoprotein as a Biomarker for Placental Adherence in Low-Lying Placenta: A Prospective Observational Study at a Tertiary Care Centre in Eastern India. International Journal of Current Pharmaceutical Review and Research, 18(07). https://doi.org/10.25258/ijcpr.18.7.12
Vancouver
V PV, Meena R, Boipai P, Mehta M, DungDung IR, Chaudhary K. Maternal Serum Alpha-Fetoprotein as a Biomarker for Placental Adherence in Low-Lying Placenta: A Prospective Observational Study at a Tertiary Care Centre in Eastern India. International Journal of Current Pharmaceutical Review and Research. 2026;18(07). doi:10.25258/ijcpr.18.7.12
BibTeX
@article{V2026,
author = {V, Priyanka V and Meena, Rajkumari and Boipai, Payal and Mehta, Meena and DungDung, Indu Rekha and Chaudhary, Kuldeep},
title = {Maternal Serum Alpha-Fetoprotein as a Biomarker for Placental Adherence in Low-Lying Placenta: A Prospective Observational Study at a Tertiary Care Centre in Eastern India},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {07},
doi = {10.25258/ijcpr.18.7.12}
}
EUVIMED